Gary Nachman Analyst PerformanceBiotech/BioPharma Equity Research Analyst at Canaccord Genuity GroupGary Nachman is a stock analyst at Canaccord Genuity Group in the healthcare sector, covering 17 publicly traded companies. Over the past year, Gary Nachman has issued 34 stock ratings, including strong buy, buy, and hold recommendations. While full access to Gary Nachman's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Gary Nachman's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access to unlock analyst rankings MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings64 Last 10 YearsBuy Recommendations75.00% 48 Buy RatingsCompanies Covered17 Unique Companies Ratings Distribution64RatingsDistribution of strong buy, buy, hold, and sell ratings by Gary Nachman.RatingPercentageCount Strong Buy18.8%12 ratings Buy56.3%36 ratings Hold20.3%13 ratings Sell4.7%3 ratingsOut of 64 total stock ratings issued by Gary Nachman at Canaccord Genuity Group, the majority (56.3%) have been Buy recommendations, followed by 20.3% Hold, 18.8% Strong Buy, and 4.7% Sell.Best & Worst CallsBest Call000.0%ABBVDec 2021Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%LENZJul 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ82.4% of companies on NASDAQ14 companiesNYSE17.6% of companies on NYSE3 companiesGary Nachman, an analyst at Canaccord Genuity Group, currently covers 17 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageHealthcare17 companies100.0%Gary Nachman of Canaccord Genuity Group specializes in stock coverage within the Healthcare sector.Coverage IndustriesIndustryPercentagePHARMACEUTICALS9 companies52.9%BIOTECHNOLOGY6 companies35.3%HEALTHCARE TECHNOLOGY1 company5.9%HEALTHCARE EQUIPMENT & SUPPLIES1 company5.9% Gary Nachman's Ratings History at Canaccord Genuity Group Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter More filters Fewer filters Done 0 Results Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsSDGRSchrodinger10/12/2026Boost Price Target$27.20$30.00Outperform$0.0000.00% ROISRRKScholar Rock10/8/2026Reiterated Rating$42.06Strong-Buy$0.0000.00% ROISRRKScholar Rock9/14/2026Boost Price Target$55.41$72.00Strong-Buy$0.0000.00% ROIIONSIonis Pharmaceuticals9/8/2026Lower Price Target$58.09$85.00Buy$0.0000.00% ROIETONEton Pharmaceuticals8/14/2026Boost Price Target$54.70$68.00Buy$0.0000.00% ROIANIPANI Pharmaceuticals8/10/2026Lower Price Target$78.25$90.00Hold$0.0000.00% ROIAMGNAmgen8/5/2026Boost Price Target$390.63$384.00Hold$0.0000.00% ROIABBVAbbVie8/3/2026Boost Price Target$251.33$290.00Buy$0.0000.00% ROIABBVAbbVie7/22/2026Boost Price Target$256.18$282.00Buy$0.0000.00% ROIJAZZJazz Pharmaceuticals7/16/2026Initiated Coverage$242.18$290.00Buy$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. ANIPANI Pharmaceuticals7/16/2026Initiated Coverage$81.92$91.00Hold$0.0000.00% ROIETONEton Pharmaceuticals7/16/2026Initiated Coverage$37.19$60.00Buy$0.0000.00% ROIETONEton Pharmaceuticals7/16/2026Upgrade$42.32Strong-Buy$0.0000.00% ROIJAZZJazz Pharmaceuticals7/16/2026Upgrade$247.53Strong-Buy$0.0000.00% ROIIONSIonis Pharmaceuticals7/10/2026Lower Price Target$64.27$95.00Buy$0.0000.00% ROIABBVAbbVie6/23/2026Boost Price Target$230.10$273.00Buy$0.0000.00% ROIADMAADMA Biologics5/7/2026Lower Price Target$10.08$18.00Buy$0.0000.00% ROIABBVAbbVie4/30/2026Boost Price Target$211.66$265.00Buy$0.0000.00% ROIABBVAbbVie4/20/2026Initiated Coverage$204.08$262.00Buy$0.0000.00% ROISRRKScholar Rock4/20/2026Initiated Coverage$47.80$62.00Buy$0.0000.00% ROIIONSIonis Pharmaceuticals4/20/2026Initiated Coverage$74.87$110.00Buy$0.0000.00% ROIADMAADMA Biologics4/20/2026Initiated Coverage$10.88$21.00Buy$0.0000.00% ROIACHVAchieve Life Sciences4/20/2026Set Price Target$4.25$13.00Buy$0.0000.00% ROIAMGNAmgen4/20/2026Initiated Coverage$350.16$366.00Hold$0.0000.00% ROIABBVAbbVie4/20/2026Upgrade$204.95Strong-Buy$0.0000.00% ROIACHVAchieve Life Sciences4/20/2026Upgrade$4.21Strong-Buy$0.0000.00% ROIADMAADMA Biologics4/20/2026Upgrade$10.78Strong-Buy$0.0000.00% ROIIONSIonis Pharmaceuticals4/20/2026Upgrade$74.78Strong-Buy$0.0000.00% ROISRRKScholar Rock4/20/2026Upgrade$48.10Strong-Buy$0.0000.00% ROIABBVAbbVie11/3/2025Set Price Target$218.14$256.00Outperform$0.0000.00% ROIBLCOBausch + Lomb10/30/2025Reiterated Rating$15.39$19.00Outperform$0.0000.00% ROIIONSIonis Pharmaceuticals10/30/2025Reiterated Rating$73.57$89.00Strong-Buy$0.0000.00% ROILENZLENZ Therapeutics10/20/2025Reiterated Rating$36.63$50.00Outperform$0.0000.00% ROIABBVAbbVie10/17/2025Reiterated Rating$226.77$250.00Outperform$0.0000.00% ROIIONSIonis Pharmaceuticals9/22/2025Set Price Target$61.36$75.00Strong-Buy$00.0000.00% ROIAMGNAmgen9/3/2025Initiated Coverage$286.07Market Perform$000.0000.00% ROIABBVAbbVie8/25/2025Reiterated Rating$207.74Outperform$000.0000.00% ROIVERUVeru8/13/2025Lower Price Target$3.17$20.00Outperform$0.0000.00% ROIABBVAbbVie8/1/2025Boost Price Target$189.02$236.00Outperform$000.0000.00% ROILENZLENZ Therapeutics7/31/2025Boost Price Target$30.98$40.00Outperform$0.0000.00% ROILouis Navellier: My #1 AI stock for 2026 (name & ticker inside) (Ad)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.Get the name and ticker of Louis Navellier's #1 AI stock freeIONSIonis Pharmaceuticals7/31/2025Boost Price Target$43.35$64.00Strong-Buy$00.0000.00% ROIABBVAbbVie2/3/2025Reiterated Rating$183.90$220.00Outperform$000.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenUBS GroupCitigroupBarclaysRoyal Bank Of CanadaMorgan StanleyWells Fargo & CompanyJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerDeutsche Bank AktiengesellschaftBMO Capital Markets Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
